This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (230)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Neurology  • Alzheimer Disease  • Dementias  • Neuropathology  • Alert me on articles by topic  Social Bookmarking   What's this?

Cerebrospinal Fluid -Amyloid_(1-42) in Alzheimer Disease

Differences Between Early- and Late-Onset Alzheimer Disease and Stability During the Course of Disease

Niels Andreasen, MD; Camilla Hesse; Pia Davidsson, PhD; Lennart Minthon, MD, PhD; Anders Wallin, MD, PhD; Bengt Winblad, MD, PhD; Hugo Vanderstichele, PhD; Eugeen Vanmechelen, PhD; Kaj Blennow, MD, PhD

Arch Neurol. 1999;56:673-680.

Objectives  To study the diagnostic potential of the 42 amino acid form of -amyloid (-amyloid_(1-42)) in cerebrospinal fluid (CSF) as a biochemical marker for Alzheimer disease (AD), the intra-individual biological variation of CSF--amyloid_(1-42) level in patients with AD, and the possible effects of differential binding between -amyloid and apolipoprotein E isoforms on CSF--amyloid_(1-42) levels.

Design  A 20-month prospective follow-up study.

Setting  Community population-based sample of consecutive patients with AD referred to the Piteå River Valley Hospital, Piteå, Sweden.

Patients  Fifty-three patients with AD (mean±SD age, 71.4±7.4 years) diagnosed according to the National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer's Disease and Related Disorders Association criteria and 21 healthy, age-matched (mean±SD age, 68.8±8.0 years) control subjects.

Main Outcome Measures  Cerebrospinal fluid -amyloid_(1-42) level—analyzed using enzyme-linked immunosorbent assay—and severity of dementia—analyzed using the Mini–Mental State Examination.

Results  Mean±SD levels of CSF--amyloid_(1-42) were decreased (P<.001) in patients with AD (709±304 pg/mL) compared with controls (1678±436 pg/mL). Most patients with AD (49 [92%] of 53 patients) had reduced levels (<1130 pg/mL). A highly significant correlation (r=0.90; P<.001) between baseline and 1-year follow-up CSF--amyloid_(1-42) levels was found. There were no significant correlations between CSF--amyloid_(1-42) level and duration (r=-0.16) or severity (r=-0.02) of dementia. Low levels were also found in patients with mild dementia (Mini–Mental State Examination score, >25).

Conclusions  The sensitivity of CSF--amyloid_(1-42) level as a diagnostic marker for AD is high. The intra-individual biological variation in CSF--amyloid_(1-42) level is low. Low CSF--amyloid_(1-42) levels are also found in the earlier stages of dementia in patients with AD. These findings suggest that CSF--amyloid_(1-42) analyses may be of value in the clinical diagnosis of AD, especially in the early course of the disease, when drug therapy may have the greatest potential of being effective but clinical diagnosis is particularly difficult.

From the Department of Rehabilitation, Piteå River Valley Hospital, Piteå (Dr Andreasen, the Units of Neurochemistry (Ms Hesse, and Drs Davidsson and Blennow) and Psychiatry (Dr Wallin), Department of Clinical Neuroscience, University of Göteborg, Sahlgren's University Hospital, Mölndal, the Department of Clinical Neuroscience, Neuropsychiatric Clinic, Malmö University Hospital, Malmö (Dr Minthon), and the Section of Geriatric Medicine, Department of Clinical Neuroscience and Family Medicine, Karolinska Institute, Huddinge University Hospital, Stockholm (Dr Winblad), Sweden; and The Medical Research Council (Dr Blennow), Sweden; and Innogenetics, Ghent, Belgium (Drs Vanderstichele and Vanmechelen).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Cerebrospinal Fluid Opens a Window on Alzheimer Disease
Douglas Galasko
Arch Neurol. 1999;56(6):655-656.
EXTRACT | FULL TEXT  

Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 1999;56(6):762-764.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway et al.
Neurology 2009;73:2061-2070.
ABSTRACT | FULL TEXT  

Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide
Hu et al.
Proc. Natl. Acad. Sci. USA 2009;106:20324-20329.
ABSTRACT | FULL TEXT  

CSF biomarkers predict rate of cognitive decline in Alzheimer disease
Kester et al.
Neurology 2009;73:1353-1358.
ABSTRACT | FULL TEXT  

CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
Mattsson et al.
JAMA 2009;302:385-393.
ABSTRACT | FULL TEXT  

Cerebrospinal Fluid Biomarkers and Rate of Cognitive Decline in Very Mild Dementia of the Alzheimer Type
Snider et al.
Arch Neurol 2009;66:638-645.
ABSTRACT | FULL TEXT  

Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease
Jack et al.
Brain 2009;132:1355-1365.
ABSTRACT | FULL TEXT  

The Brain Injury Biomarker VLP-1 Is Increased in the Cerebrospinal Fluid of Alzheimer Disease Patients
Lee et al.
Clin. Chem. 2008;54:1617-1623.
ABSTRACT | FULL TEXT  

Continuous CSF drainage in AD: Results of a double-blind, randomized, placebo-controlled study
Silverberg et al.
Neurology 2008;71:202-209.
ABSTRACT | FULL TEXT  

CSF biomarkers in frontotemporal lobar degeneration with known pathology
Bian et al.
Neurology 2008;70:1827-1835.
ABSTRACT | FULL TEXT  

Plasma {beta} Amyloid and the Risk of Alzheimer Disease and Dementia in Elderly Men: A Prospective, Population-Based Cohort Study
Sundelof et al.
Arch Neurol 2008;65:256-263.
ABSTRACT | FULL TEXT  

Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies
Nielsen et al.
Neurology 2007;69:1569-1579.
ABSTRACT | FULL TEXT  

Longitudinal changes of CSF biomarkers in memory clinic patients
Bouwman et al.
Neurology 2007;69:1006-1011.
ABSTRACT | FULL TEXT  

FLUCTUATIONS OF CSF AMYLOID-{beta} LEVELS: IMPLICATIONS FOR A DIAGNOSTIC AND THERAPEUTIC BIOMARKER
Shi and Bateman
Neurology 2007;69:1063-1065.
FULL TEXT  

No association of CSF biomarkers with APOE{varepsilon}4, plaque and tangle burden in definite Alzheimer's disease
Engelborghs et al.
Brain 2007;130:2320-2326.
ABSTRACT | FULL TEXT  

Cerebrospinal fluid {beta}-amyloid 1-42 concentration may predict cognitive decline in older women
Gustafson et al.
J. Neurol. Neurosurg. Psychiatry 2007;78:461-464.
ABSTRACT | FULL TEXT  

Fluctuations of CSF amyloid-ss levels: Implications for a diagnostic and therapeutic biomarker
Bateman et al.
Neurology 2007;68:666-669.
ABSTRACT | FULL TEXT  

Associations between white matter lesions, cerebrovascular risk factors, and low CSF Abeta42.
Stenset et al.
Neurology 2006;67:830-833.
ABSTRACT | FULL TEXT  

Neurochemical aftermath of amateur boxing.
Zetterberg et al.
Arch Neurol 2006;63:1277-1280.
ABSTRACT | FULL TEXT  

Usefulness of Longitudinal Measurements of {beta}-Amyloid1-42 in Cerebrospinal Fluid of Patients with Various Cognitive and Neurologic Disorders.
Bouwman et al.
Clin. Chem. 2006;52:1604-1606.
FULL TEXT  

Simultaneous Measurement of {beta}-Amyloid(1-42), Total Tau, and Phosphorylated Tau (Thr181) in Cerebrospinal Fluid by the xMAP Technology
Olsson et al.
Clin. Chem. 2005;51:336-345.
ABSTRACT | FULL TEXT  

A cladistic model of ACE sequence variation with implications for myocardial infarction, Alzheimer disease and obesity
Katzov et al.
Hum Mol Genet 2004;13:2647-2657.
ABSTRACT | FULL TEXT  

Amyloid {beta}(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease
Schoonenboom et al.
Neurology 2004;62:1580-1584.
ABSTRACT | FULL TEXT  

Plasma Levels of {beta}-Amyloid(1-40), {beta}-Amyloid(1-42), and Total {beta}-Amyloid Remain Unaffected in Adult Patients With Hypercholesterolemia After Treatment With Statins
Hoglund et al.
Arch Neurol 2004;61:333-337.
ABSTRACT | FULL TEXT  

Intrathecal inflammation precedes development of Alzheimer's disease
Tarkowski et al.
J. Neurol. Neurosurg. Psychiatry 2003;74:1200-1205.
ABSTRACT | FULL TEXT  

Cerebrospinal Fluid Markers in Dementia With Lewy Bodies Compared With Alzheimer Disease
Gomez-Tortosa et al.
Arch Neurol 2003;60:1218-1222.
ABSTRACT | FULL TEXT  

Age but Not Diagnosis Is the Main Predictor of Plasma Amyloid {beta}-Protein Levels
Fukumoto et al.
Arch Neurol 2003;60:958-964.
ABSTRACT | FULL TEXT  

The {gamma}-Secretase Inhibitor N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl Ester Reduces A{beta} Levels in Vivo in Plasma and Cerebrospinal Fluid in Young (Plaque-Free) and Aged (Plaque-Bearing) Tg2576 Mice
Lanz et al.
J. Pharmacol. Exp. Ther. 2003;305:864-871.
ABSTRACT | FULL TEXT  

Decreased {beta}-Amyloid1-42 and Increased Tau Levels in Cerebrospinal Fluid of Patients With Alzheimer Disease
Sunderland et al.
JAMA 2003;289:2094-2103.
ABSTRACT | FULL TEXT  

Haplotypes extending across ACE are associated with Alzheimer's disease
Kehoe et al.
Hum Mol Genet 2003;12:859-867.
ABSTRACT | FULL TEXT  

CSF A{beta} 42 levels correlate with amyloid-neuropathology in a population-based autopsy study
Strozyk et al.
Neurology 2003;60:652-656.
ABSTRACT | FULL TEXT  

Cerebrospinal Fluid Tau and {beta}-Amyloid 42 Proteins Identify Alzheimer Disease in Subjects With Mild Cognitive Impairment
Riemenschneider et al.
Arch Neurol 2002;59:1729-1734.
ABSTRACT | FULL TEXT  

Tau and A{beta}42 protein in CSF of patients with frontotemporal degeneration
Riemenschneider et al.
Neurology 2002;58:1622-1628.
ABSTRACT | FULL TEXT  

Levels of Nonphosphorylated and Phosphorylated Tau in Cerebrospinal Fluid of Alzheimer's Disease Patients : An Ultrasensitive Bienzyme-Substrate-Recycle Enzyme-Linked Immunosorbent Assay
Hu et al.
Am. J. Pathol. 2002;160:1269-1278.
ABSTRACT | FULL TEXT  

Amyloid precursor protein in platelets: A peripheral marker for the diagnosis of sporadic AD
Padovani et al.
Neurology 2001;57:2243-2248.
ABSTRACT | FULL TEXT  

Tau and A{beta}42 in Cerebrospinal Fluid from Healthy Adults 21-93 Years of Age: Establishment of Reference Values
Sjogren et al.
Clin. Chem. 2001;47:1776-1781.
ABSTRACT | FULL TEXT  

{beta}-Amyloid Activates the Mitogen-Activated Protein Kinase Cascade via Hippocampal {alpha}7 Nicotinic Acetylcholine Receptors: In Vitro and In Vivo Mechanisms Related to Alzheimer's Disease
Dineley et al.
J. Neurosci. 2001;21:4125-4133.
ABSTRACT | FULL TEXT  

Practice parameter: Diagnosis of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology
Knopman et al.
Neurology 2001;56:1143-1153.
ABSTRACT | FULL TEXT  

Evaluation of CSF-tau and CSF-A{beta}42 as Diagnostic Markers for Alzheimer Disease in Clinical Practice
Andreasen et al.
Arch Neurol 2001;58:373-379.
ABSTRACT | FULL TEXT  

Age-Dependent Changes in Brain, CSF, and Plasma Amyloid {beta} Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease
Kawarabayashi et al.
J. Neurosci. 2001;21:372-381.
ABSTRACT | FULL TEXT  

TNF gene polymorphism and its relation to intracerebral production of TNF{alpha} and TNF{beta} in AD
Tarkowski et al.
Neurology 2000;54:2077-2081.
ABSTRACT | FULL TEXT  

Decreased {beta}-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease
Otto et al.
Neurology 2000;54:1099-1102.
ABSTRACT | FULL TEXT  

Cerebrospinal Fluid Opens a Window on Alzheimer Disease
Galasko
Arch Neurol 1999;56:655-656.
FULL TEXT